Abstract
Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ), raise concerns for the elimination of Plasmodium vivax. The absence of an effective molecular marker of CQ resistance in P. vivax greatly constrains surveillance of this emerging threat. A recent genetic cross between CQ sensitive (CQS) and CQ resistant (CQR) NIH-1993 strains of P. vivax linked a moderate CQR phenotype with two candidate markers in P. vivax CQ resistance transporter gene (pvcrt-o): MS334 and In9pvcrt. Longer TGAAGH motifs at MS334 were associated with CQ resistance, as were shorter motifs at the In9pvcrt locus. In this study, high-grade CQR clinical isolates of P. vivax from Malaysia were used to investigate the association between the MS334 and In9pvcrt variants and treatment efficacy. Amongst a total of 49 independent monoclonal P. vivax isolates assessed, high-quality MS334 and In9pvcrt sequences could be derived from 30 (61%) and 23 (47%), respectively. Five MS334 and six In9pvcrt alleles were observed, with allele frequencies ranging from 2 to 76% and 3 to 71%, respectively. None of the clinical isolates had the same variant as the NIH-1993 CQR strain, and none were associated with CQ treatment failure (all p>0.05). Our findings suggest that the pvcrt-o MS334 and In9pvcrt markers cannot be used universally as markers of CQ treatment efficacy in an area of high-grade CQ resistance. Further studies applying hypothesis-free genome-wide approaches are warranted to identify more effective CQR markers for P. vivax.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the National Health and Medical Research Council (NHMRC) Australia Ideas Grant (APP2001083) awarded to SA, program Grant 1037304, project grant 1045156, and a Senior Principal Research Fellowship to NMA (1135820)], Malaysian Ministry of Health (grant BP00500420), and the AusAID Asia-Pacific Malaria Elimination Network (grant 108-07). The work was also supported by the Australian Centre for Research Excellence on Malaria Elimination (ACREME), funded by the National Health and Medical Research Council of Australia (APP1134989).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were collected with written informed consent from patient or legal guardian for individuals less than 18 years of age. Ethical approval for the patient sampling and parasite molecular analysis was provided by the Human Research Ethics Committee of the Northern Territory Department of Health and Families (HREC-2010-1431, HREC-2012-1815 and HREC-2010-1396), the National Medical Research Ethics Committee, Ministry of Health, Malaysia (NMMR-10-754-6684, NMRR-12-511-12579).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript